- Conditions
- Thrombocythemia, Essential, Primary Myelofibrosis
- Interventions
- Bomedemstat
- Drug
- Lead sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 5
- States / cities
- Miami, Florida • Ann Arbor, Michigan • Cleveland, Ohio + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 2,082
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Nipocalimab, Placebo, Standard of care treatment
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 38
- States / cities
- Beverly Hills, California • Fullerton, California • Hemet, California + 33 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Macitentan
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 550 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2020
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 32 more
- Conditions
- Primary Mitochondrial Myopathy
- Interventions
- Bocidelpar, Placebo
- Drug
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 11
- States / cities
- La Jolla, California • Stanford, California • Aurora, Colorado + 7 more
- Conditions
- Primary Sclerosing Cholangitis
- Interventions
- Cilofexor, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 419 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 82
- States / cities
- Glendale, Arizona • Phoenix, Arizona • Coronado, California + 65 more
- Conditions
- Healthy
- Interventions
- Tramodol Extended-Release (ER)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Oakland, California • Miami, Florida + 20 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting, Clinically Isolated Syndrome
- Interventions
- Tovaxin
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 27
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Berkeley, California + 23 more
- Conditions
- Sickle Cell Disease
- Interventions
- ICL670
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 185 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 31
- States / cities
- Mobile, Alabama • Loma Linda, California • Los Angeles, California + 25 more
- Conditions
- Peanut Allergy, Multi-food Allergy
- Interventions
- Omalizumab, Placebo for Omalizumab, Multi-Allergen Oral Immunotherapy, Placebo for Multi-Allergen Oral Immunotherapy, Double-Blind Placebo-Controlled Food Challenge Based Treatment
- Drug · Other
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 1 Year to 55 Years
- Enrollment
- 458 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Stanford, California • Denver, Colorado + 7 more
- Conditions
- Crohn's Disease
- Interventions
- PF-04236921
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 191 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 62
- States / cities
- Scottsdale, Arizona • Tucson, Arizona • Lakewood, Colorado + 30 more
- Conditions
- Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
- Interventions
- AK002
- Drug
- Lead sponsor
- Allakos Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more
- Conditions
- Hemophilic Arthropathy
- Interventions
- TRM-201 (Rofecoxib), Placebo
- Drug
- Lead sponsor
- Tremeau Pharmceuticals, Inc.
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 19
- States / cities
- Los Angeles, California • Orange, California • Sacramento, California + 15 more
- Conditions
- Amyotrophic Lateral Sclerosis (ALS)
- Interventions
- VHB937, Placebo
- Biological · Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 21
- States / cities
- La Jolla, California • Loma Linda, California • Los Angeles, California + 18 more
- Conditions
- Advanced Stage Parkinson's Disease
- Interventions
- Pardoprunox
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 14
- States / cities
- La Jolla, California • San Francisco, California • Fort Lauderdale, Florida + 11 more
- Conditions
- Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
- Interventions
- INZ-701
- Drug
- Lead sponsor
- Inozyme Pharma
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 2
- States / cities
- Rochester, Minnesota • Eatontown, New Jersey
- Conditions
- Acute Myeloid Leukemia, Myeloid Dysplastic Syndrome
- Interventions
- Guadecitabine
- Drug
- Lead sponsor
- Astex Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 5
- States / cities
- Buffalo, New York • Durham, North Carolina • Columbus, Ohio + 2 more
- Conditions
- Investigation of Platelet Aggregation in Paediatric Patients With Sickle Cell Disease
- Interventions
- Ticagrelor Dose 1a + Dose 2a, Ticagrelor Dose 1b + Dose 2b
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 6
- States / cities
- Orange, California • Chicago, Illinois • Detroit, Michigan + 3 more
- Conditions
- Arthritis, Juvenile
- Interventions
- Golimumab, Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 14
- States / cities
- San Diego, California • Chicago, Illinois • Boston, Massachusetts + 11 more
- Conditions
- Crohn's Disease
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 12
- States / cities
- Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more
- Conditions
- Tourette Syndrome in Children, Tourette Syndrome in Adolescence
- Interventions
- Ecopipam
- Drug
- Lead sponsor
- Emalex Biosciences Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 53
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 45 more
- Conditions
- Major Depressive Disorder (MDD), Major Depressive Disorder With Anxious Distress
- Interventions
- SPT-300
- Drug
- Lead sponsor
- Seaport Therapeutics
- Industry
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 20
- States / cities
- Chino, California • Garden Grove, California • Glendale, California + 17 more
- Conditions
- Dry Age-related Macular Degeneration
- Interventions
- Valeda Light Delivery System
- Device
- Lead sponsor
- LumiThera, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Beverly Hills, California • Palo Alto, California • Altamonte Springs, Florida + 4 more
- Conditions
- Prader-Willi Syndrome, Hyperphagia
- Interventions
- Livoletide, Placebo
- Drug
- Lead sponsor
- Millendo Therapeutics SAS
- Industry
- Eligibility
- 4 Years to 65 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 15
- States / cities
- Birmingham, Alabama • Orange, California • San Diego, California + 12 more